银屑病患者甲氨蝶呤药物生存的决定因素:按停药原因分层的MTX-CAPTURE前瞻性研究
该前瞻性队列研究纳入85例接受甲氨蝶呤治疗的银屑病患者,按停药原因分层分析5年药物生存率及决定因素。65%患者停药,副作用(35%)比疗效不足(26%)更常见。基线PASI评分高和疾病严重度VAS评分高可能是短药物生存的决定因素。
要点
- 停药主因是副作用(35%),其次为疗效不足(26%)。
- 基线PASI和疾病严重度VAS评分高可能预示短药物生存。
核心结论
- 甲氨蝶呤在银屑病患者中药物生存率低,5年仅15%患者仍在用药。
- 副作用单独或合并疗效不足比单独疗效不足更重要地导致停药。
研究设计与样本
- 采用Kaplan-Meier法分析药物生存率,Cox回归分析停药决定因素,按副作用或疗效不足分层分析。
主要发现
- 55例(65%)停药:副作用35%、疗效不足26%、副作用合并疗效不足13%、其他原因16%、失访11%。
- 最常见副作用为胃肠道症状,尽管99%患者使用叶酸。
- 单因素分析显示基线PASI评分高和疾病严重度VAS评分高可能是短药物生存的决定因素。
临床怎么用
- 临床应关注甲氨蝶呤治疗银屑病的副作用管理,尤其胃肠道症状,以提高药物生存。
- 基线PASI和疾病严重度VAS评分高的患者可能需更密切监测或考虑替代治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As methotrexate (MTX) is a widely used treatment for psoriasis, it is important to gain insight into the reasons for the discontinuation of MTX and to understand the determinants for drug survival. OBJECTIVES: To describe 5-year drug survival for MTX in patients with psoriasis, split according to different reasons for discontinuation, and to identify the determinants for drug survival. METHODS: Data were extracted from a prospective psoriasis registry of patients treated with MTX (MTX-CAPTURE). Drug survival was analysed using Kaplan-Meier estimates and the determinants for discontinuation were analysed using Cox regression analysis. Analyses were split according to the reason for discontinuation: side-effects or ineffectiveness. RESULTS: We included 85 patients treated with MTX, with a maximum treatment duration of 5·2 years. The overall drug survival rates were 63%, 30% and 15% after 1, 3 and 5 years, respectively. The median survival was 1·8 years. Overall, 55 patients (65%) discontinued MTX for the following reasons: side-effects (35%), ineffectiveness (26%), combination of side-effects and ineffectiveness (13%), other reasons (16%) and 11% were lost to follow-up. The most reported side-effects were gastrointestinal symptoms, despite the use of folic acid in 99% of patients. Based on univariate analysis, a high Psoriasis Area and Severity Index score and a high score on the visual analogue scale for disease severity at baseline were possible determinants for a short drug survival. CONCLUSIONS: Drug survival of MTX was low with 15% of patients 'on drug' after 5 years. Side-effects alone or in combination with inadequate disease control were more important in the context of treatment discontinuation than inadequate disease control alone.
引用
- Otero ME, van den Reek JM, Seyger MM, et al. Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation: results of the prospective MTX-CAPTURE. Br J Dermatol. 2017. PMID: 28078672. doi:10.1111/bjd.15305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。